Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.2%

Autolus Therapeutics plc (NASDAQ:AUTL) dropped 5.2% during trading on Friday . The stock traded as low as $4.53 and last traded at $4.55. Approximately 922,414 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 1,501,885 shares. The stock had previously closed at $4.80.

Analyst Ratings Changes

AUTL has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Friday, April 12th. Truist Financial boosted their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.16.

Autolus Therapeutics Price Performance

The firm has a market cap of $1.20 billion, a PE ratio of -3.80 and a beta of 1.90. The stock’s fifty day moving average price is $5.89 and its 200-day moving average price is $5.12.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). On average, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC grew its holdings in shares of Autolus Therapeutics by 6.6% in the first quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock valued at $18,124,000 after purchasing an additional 268,818 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $19,328,000. Perpetual Ltd grew its holdings in shares of Autolus Therapeutics by 8.2% in the first quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after purchasing an additional 169,784 shares during the period. Affinity Asset Advisors LLC grew its holdings in shares of Autolus Therapeutics by 25.4% in the third quarter. Affinity Asset Advisors LLC now owns 1,992,466 shares of the company’s stock valued at $4,642,000 after purchasing an additional 403,449 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $11,793,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.